GlaxoSmithKline and Sanofi have teamed up to develop the covid-19 vaccine

wednesday morning, the number of covid-19 (coronavirus) cases recorded in the UK had reached 93,873, with 12,107 deaths. Pharmaceutical giants GlaxoSmithKline and Sanofi are teaming up to develop a adage covid-19 vaccine.Under the partnership, Sanofi will contribute its s protein covid-19 antigen, which is based on recombinant DNA technology. According to the companies, the technology has produced genes that exactly match the proteins found on the surface of the virus, and the DNA sequence that encodes the antigen has been integrated into the DNA of the rod virus expression platform, which is the basis for Sanofi's licensed recombinant influenza products in the United States.GlaxoSmithKline will contribute to its proven pandemic ad technology, which aims to enhance the immune response to vaccines, especially in pandemic situations, because it reduces the amount of protein needed for each dose of vaccine. GlaxoSmithKline CEO Emma Shgen said: "It's a very good time to be a part of the company. "This partnership brings together two of the world's largest vaccine companies," Walmsley said. By combining our science and technology, we believe we can help accelerate global efforts to develop vaccines to protect as many people as possible from covid-19.as Sanofi previously announced, the development of a recombined covid-19 candidate vaccine is being supported through funding and collaboration with the U.S. Biomedical Advanced Research and Development Authority (BARDA). Strategic alliances among vaccine industry leaders are critical to producing a coronavirus vaccine as soon as possible," balda director Rick S. "The development of a vaccine candidate for covid-19 based on adrenal recombination has the potential to reduce vaccine doses and provide more people with vaccines to end the pandemic, help the world prepare better, and even prevent future coronavirus outbreaks," Bright commented.the two companies have formed a joint collaborative working group, co-chaired by David Loew, Sanofi's global head of vaccines, and Roger Connor, President of GlaxoSmithKline Vaccines, which will seek resources from both companies to find every opportunity to accelerate the development of vaccine candidates. （cyy123.com）